Drug Trial Radar · NCT06580301
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Sep 25, 2024
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Excyte Biopharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).
Conditions
- B-cell Acute Lymphoblastic Leukemia
Interventions
YK012Drug
The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Incidence and Profile of Dose-limiting Toxicity (DLT)Time frame: 28 days after the first dose
- Maximum Tolerated dose (MTD) or The Recommended Dose for Future Clinical StudyTime frame: Through study completion, 20 weeks
- Number of Participants with Adverse EventsTime frame: From the time the participant signs the ICF until the end of the safety visit period, assessed up to 24weeks.
- Number of Participants with Serious Adverse EventsTime frame: From the time the participant signs the ICF until the end of the safety visit period, assessed up to 24weeks.
- Dose Expansion Phase: Objective Response Rate (ORR)Time frame: From the time the participant signs the ICF until hematological relapse, assessed up to 1 year
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.